DNA Link Inc (127120) - Net Assets
Based on the latest financial reports, DNA Link Inc (127120) has net assets worth ₩89.37 Billion KRW (≈ $60.56 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩143.32 Billion ≈ $97.13 Million USD) and total liabilities (₩53.95 Billion ≈ $36.56 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore DNA Link Inc asset portfolio for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩89.37 Billion |
| % of Total Assets | 62.36% |
| Annual Growth Rate | 13.59% |
| 5-Year Change | 109.31% |
| 10-Year Change | 3677.97% |
| Growth Volatility | 328.97 |
DNA Link Inc - Net Assets Trend (2011–2025)
This chart illustrates how DNA Link Inc's net assets have evolved over time, based on quarterly financial data. Check tangible equity quality of DNA Link Inc to evaluate the tangible quality of the company's equity base.
Annual Net Assets for DNA Link Inc (2011–2025)
The table below shows the annual net assets of DNA Link Inc from 2011 to 2025. For live valuation and market cap data, see DNA Link Inc (127120) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩68.59 Billion ≈ $46.48 Million |
+174.05% |
| 2024-12-31 | ₩25.03 Billion ≈ $16.96 Million |
-4.75% |
| 2023-12-31 | ₩26.28 Billion ≈ $17.81 Million |
-5.78% |
| 2022-12-31 | ₩27.89 Billion ≈ $18.90 Million |
-14.89% |
| 2021-12-31 | ₩32.77 Billion ≈ $22.21 Million |
-15.33% |
| 2020-12-31 | ₩38.70 Billion ≈ $26.23 Million |
+300.56% |
| 2019-12-31 | ₩9.66 Billion ≈ $6.55 Million |
-50.71% |
| 2018-12-31 | ₩19.60 Billion ≈ $13.29 Million |
-17.13% |
| 2017-12-31 | ₩23.66 Billion ≈ $16.03 Million |
+1203.01% |
| 2016-12-31 | ₩1.82 Billion ≈ $1.23 Million |
-83.79% |
| 2015-12-31 | ₩11.20 Billion ≈ $7.59 Million |
+44.87% |
| 2014-12-31 | ₩7.73 Billion ≈ $5.24 Million |
-56.32% |
| 2012-12-31 | ₩17.70 Billion ≈ $12.00 Million |
+53.68% |
| 2011-12-31 | ₩11.52 Billion ≈ $7.81 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to DNA Link Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9530894516000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩171.17 Billion | 249.54% |
| Total Equity | ₩68.59 Billion | 100.00% |
DNA Link Inc Competitors by Market Cap
The table below lists competitors of DNA Link Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Metallus, Inc
NYSE:MTUS
|
$762.21 Million |
|
Weihai Honglin Electronic Co. Ltd. A
SHE:301439
|
$762.40 Million |
|
EuroTeleSites AG
F:7YF
|
$762.51 Million |
|
Sgis Songshan Co Ltd
SHE:000717
|
$762.57 Million |
|
Tamar Petroleum Ltd
TA:TMRP
|
$761.90 Million |
|
OCI NV
AS:OCI
|
$761.80 Million |
|
Ethos Limited
NSE:ETHOSLTD
|
$761.75 Million |
|
JC Finance & Tax Interconnect Holdings Ltd
SHE:002530
|
$761.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DNA Link Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 25,029,674,160 to 68,592,952,210, a change of 43,563,278,050 (174.0%).
- Net loss of 16,445,157,060 reduced equity.
- New share issuances of 42,000,010,190 increased equity.
- Other factors increased equity by 18,008,424,920.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-16.45 Billion | -23.97% |
| Share Issuances | ₩42.00 Billion | +61.23% |
| Other Changes | ₩18.01 Billion | +26.25% |
| Total Change | ₩- | 174.05% |
Book Value vs Market Value Analysis
This analysis compares DNA Link Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.21x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 119.86x to 16.21x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩271.99 | ₩32600.00 | x |
| 2017-12-31 | ₩2072.21 | ₩32600.00 | x |
| 2018-12-31 | ₩1717.22 | ₩32600.00 | x |
| 2019-12-31 | ₩791.89 | ₩32600.00 | x |
| 2020-12-31 | ₩2360.94 | ₩32600.00 | x |
| 2021-12-31 | ₩1999.03 | ₩32600.00 | x |
| 2022-12-31 | ₩1631.61 | ₩32600.00 | x |
| 2023-12-31 | ₩1537.27 | ₩32600.00 | x |
| 2024-12-31 | ₩1113.23 | ₩32600.00 | x |
| 2025-12-31 | ₩2011.68 | ₩32600.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DNA Link Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -85.14%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.79x
- Recent ROE (-23.97%) is above the historical average (-83.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -57.67% | -51.06% | 0.43x | 2.65x | ₩-5.23 Billion |
| 2015 | -80.83% | -96.12% | 0.29x | 2.92x | ₩-10.17 Billion |
| 2016 | -540.40% | -85.44% | 0.44x | 14.24x | ₩-9.99 Billion |
| 2017 | 1.43% | 2.33% | 0.58x | 1.06x | ₩-2.03 Billion |
| 2018 | -19.14% | -25.23% | 0.42x | 1.79x | ₩-5.71 Billion |
| 2019 | -135.76% | -84.24% | 0.60x | 2.68x | ₩-14.08 Billion |
| 2020 | -33.76% | -85.48% | 0.29x | 1.36x | ₩-16.94 Billion |
| 2021 | -15.56% | -22.18% | 0.56x | 1.25x | ₩-8.38 Billion |
| 2022 | -27.90% | -45.82% | 0.39x | 1.56x | ₩-10.57 Billion |
| 2023 | -21.30% | -25.50% | 0.57x | 1.47x | ₩-8.22 Billion |
| 2024 | -43.16% | -67.90% | 0.29x | 2.17x | ₩-13.30 Billion |
| 2025 | -23.97% | -85.14% | 0.16x | 1.79x | ₩-23.30 Billion |
Industry Comparison
This section compares DNA Link Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $241,483,272,525
- Average return on equity (ROE) among peers: -12.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DNA Link Inc (127120) | ₩89.37 Billion | -57.67% | 0.60x | $762.16 Million |
| ORIENTBIO Inc. (002630) | $97.94 Billion | -19.53% | 0.76x | $85.18 Million |
| Green Cross (005250) | $218.85 Billion | 4.49% | 0.86x | $280.76 Million |
| Green Cross Holdings Preference Shares (005257) | $1.31 Trillion | 5.00% | 0.57x | $2.56 Million |
| Pharmicell (005690) | $55.99 Billion | -70.00% | 0.14x | $435.51 Million |
| GeneOne Life Science Inc (011000) | $98.51 Billion | -18.93% | 0.39x | $164.07 Million |
| HLB Co. Ltd (028300) | $479.75 Billion | -16.69% | 0.47x | $2.74 Billion |
| Mgenplus Co. Ltd. (032790) | $17.38 Billion | 0.00% | 1.46x | $13.92 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $36.31 Billion | 4.18% | 0.71x | $16.61 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $26.05 Million |
| Hyundai Bioscience Co. Ltd (048410) | $51.22 Billion | -16.80% | 0.80x | $391.16 Million |
About DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more